{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:10:02Z","timestamp":1791544202847,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"am","delay-in-days":290,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jgo.2023.101681","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T12:53:55Z","timestamp":1702731235000},"page":"101681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty"],"prefix":"10.1016","volume":"15","author":[{"given":"Meena N.","family":"Murugappan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bellinda L.","family":"King-Kallimanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu","family":"Kanapuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel F.","family":"Farley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall D.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Stenehjem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica G.","family":"Horodniceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Kluetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jgo.2023.101681_bb0005","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jgo.2023.101681_bb0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jgo.2023.101681_bb0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11899-019-00500-4","article-title":"Challenges and strategies in the management of multiple myeloma in the elderly population","volume":"14","author":"Zanwar","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"10.1016\/j.jgo.2023.101681_bb0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Elderly patients with multiple myeloma: towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"13","key":"10.1016\/j.jgo.2023.101681_bb0025","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.jgo.2023.101681_bb0030","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III first trial","volume":"34","author":"Hulin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2023.101681_bb0035","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","article-title":"Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989","volume":"46","author":"Schaapveld","year":"2010","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2023.101681_bb0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2012.067058","article-title":"Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials","volume":"98","author":"Palumbo","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jgo.2023.101681_bb0045","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jgo.2023.101681_bb0050","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2014.110296","article-title":"Age and aging in blood disorders: multiple myeloma","volume":"99","author":"Sonja","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jgo.2023.101681_bb0055","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","article-title":"Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age","volume":"105","author":"Engelhardt","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jgo.2023.101681_bb0060","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.jgo.2023.101681_bb0065","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jgo.2023.101681_bb0070","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK myeloma research alliance risk profile): a development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.jgo.2023.101681_bb0075","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jgo.2023.101681_bb0080","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jgo.2018.10.010","article-title":"Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older","volume":"10","author":"Murillo","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2023.101681_bb0085","first-page":"2","article-title":"Development of a medicare health outcomes survey deficit-accumulation frailty index and its application to older patients with newly diagnosed multiple myeloma","author":"Mian","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.jgo.2023.101681_bb0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/CCI.19.00094","article-title":"Frailty in older adults with multiple myeloma: a study of US veterans","volume":"4","author":"Patel","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"issue":"2","key":"10.1016\/j.jgo.2023.101681_bb0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jgo.2019.07.004","article-title":"A comparison of three different approaches to defining frailty in older patients with multiple myeloma","volume":"11","author":"Isaacs","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.jgo.2023.101681_bb0100","first-page":"5","article-title":"Relapsed or relapsed\/refractory multiple myeloma","volume":"4","author":"Kurtin","year":"2013","journal-title":"J Adv Pract Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2023.101681_bb0105","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2023.101681_bb0110","doi-asserted-by":"crossref","DOI":"10.1007\/s11136-023-03390-5","article-title":"Measuring frailty using patient-reported outcomes (PRO) data: a feasibility study in patients with multiple myeloma","author":"Murugappan","year":"2023","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.jgo.2023.101681_bb0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.jgo.2023.101681_bb0120","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jgo.2023.101681_bb0125","author":"EORTC"},{"issue":"23","key":"10.1016\/j.jgo.2023.101681_bb0130","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1182\/blood.V126.23.4239.4239","article-title":"A frailty scale predicts outcomes of patients with newly diagnosed multiple myeloma who are ineligible for transplant treated with continuous lenalidomide plus low-dose dexamethasone on the first trial","volume":"126","author":"Facon","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2023.101681_bb0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ Psychol Meas"},{"issue":"3","key":"10.1016\/j.jgo.2023.101681_bb0140","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(19)30011-0","article-title":"Frailty in multiple myeloma: the need for harmony to prevent doing harm","volume":"6","author":"Zweegman","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.jgo.2023.101681_bb0145","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma\u2014a frailty position paper of the European myeloma network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jgo.2023.101681_bb0150","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/s41375-020-0712-5","article-title":"Simplified frailty assessment tools: are we really capturing frailty or something else?","volume":"34","author":"Giri","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jgo.2023.101681_bb0155","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jgo.2023.101681_bb0160","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Monika","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jgo.2023.101681_bb0165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3324\/haematol.2017.174573","article-title":"From transplant to novel cellular therapies in multiple myeloma: European myeloma network guidelines and future perspectives","volume":"103","author":"Gay","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jgo.2023.101681_bb0170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.14283\/jfa.2019.25","article-title":"Comparison of frailty scores in newly diagnosed patients with multiple myeloma: a review","volume":"8","author":"Mian","year":"2019","journal-title":"J Frailty Aging"},{"key":"10.1016\/j.jgo.2023.101681_bb0175","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1100\/tsw.2001.58","article-title":"Accumulation of deficits as a proxy measure of aging","volume":"1","author":"Mitnitski","year":"2001","journal-title":"ScientificWorldJournal"},{"issue":"10","key":"10.1016\/j.jgo.2023.101681_bb0180","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1177\/0898264318793469","article-title":"Cohort trends in the gender distribution of household tasks in the United States and the implications for understanding disability","volume":"31","author":"Sheehan","year":"2019","journal-title":"J Aging Health"},{"issue":"4","key":"10.1016\/j.jgo.2023.101681_bb0185","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1093\/geronj\/48.4.S204","article-title":"Measurement of need for assistance with daily activities: quantifying the influence of gender roles","volume":"48","author":"Allen","year":"1993","journal-title":"J Gerontol"},{"issue":"4","key":"10.1016\/j.jgo.2023.101681_bb0190","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/geronb\/gbw209","article-title":"Gendered expectations distort male\u2013female differences in instrumental activities of daily living in later adulthood","volume":"74","author":"Sheehan","year":"2017","journal-title":"J Gerontol B"},{"issue":"15_suppl","key":"10.1016\/j.jgo.2023.101681_bb0195","doi-asserted-by":"crossref","first-page":"8028","DOI":"10.1200\/JCO.2019.37.15_suppl.8028","article-title":"Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): frailty subgroup analysis from phase III ASPIRE and ENDEAVOR","volume":"37","author":"Facon","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2023.101681_bb0200","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-020-0713-4","article-title":"Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities","volume":"34","author":"Stege","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jgo.2023.101681_bb0205","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/cncr.33238","article-title":"Discrepancies between genitourinary cancer patients\u2019 and clinicians\u2019 characterization of the Eastern cooperative oncology group performance status","volume":"127","author":"Bergerot","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jgo.2023.101681_bb0210","article-title":"Performance status agreement assessed by the patient and clinician in a rapid access lung cancer service: can either predict completion of treatment?","volume":"28","author":"Collins","year":"2019","journal-title":"Eur J Cancer Care"},{"issue":"9","key":"10.1016\/j.jgo.2023.101681_bb0215","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clon.2020.06.016","article-title":"Beyond performance status","volume":"32","author":"Simcock","year":"2020","journal-title":"Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2023.101681_bb0220","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2021-145977","article-title":"The accuracy of the International Myeloma Working Group frailty score in capturing health-related quality of life profile of patients with relapsed refractory multiple myeloma","volume":"138","author":"Efficace","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2023.101681_bb0225","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jgs.18054","article-title":"Patient-reported geriatric assessment-based frailty index among older adults with gastrointestinal malignancies","volume":"71","author":"Giri","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.jgo.2023.101681_bb0230","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.22495","article-title":"A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation","volume":"109","author":"Mohile","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2023.101681_bb0235","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jgo.2017.09.007","article-title":"The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed\/refractory multiple myeloma in the era of novel therapies","volume":"9","author":"Hari","year":"2018","journal-title":"J Geriatr Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jgo.2023.101681_bb0240","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2017.35.15_suppl.10009","article-title":"FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. food and drug administration","volume":"35","author":"Singh","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406823005787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406823005787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:58:57Z","timestamp":1761818337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406823005787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1879406823005787"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101681","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101681"}}